Loading…
Develops inhaled formulations of approved fibrosis drugs (pirfenidone) to treat idiopathic pulmonary fibrosis with fewer side effects.
Develops inhaled formulations of approved fibrosis drugs (pirfenidone) to treat idiopathic pulmonary fibrosis with fewer side effects.
Has no approved product, so it is funded by share sales while AP01 is tested; any future income would come from selling the drug or licensing it. Because pirfenidone is already approved, the route can lean on its known safety record, but the inhaled form must still prove itself in its own trials.
Moat: narrow (IP / patents). Inhaled delivery of a known antifibrotic could reduce systemic toxicity versus oral competitors.
Headquarters: Seattle, Washington, US · Founded: 2019 · Employees: 50
Size Avalyn Pharma (AVLN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.29B, the 2085th largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.15 on 6 Nov 2026.
Performance Over six months the shares gained 6.7%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Capital Return on invested capital runs 127.6 points below its cost of capital (13.2% WACC).
Short interest Short interest is 5.3% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$42,000 | -$29,000 |
| EBITDA | n/a | -$91.2M | -$55.7M |
| Net income | n/a | -$85.2M | -$49.7M |
| Free cash flow | n/a | -$81.8M | -$48.5M |
| Capital expenditure | n/a | $344,000 | $95,000 |
| Total debt | $17.1M | $1.67M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Avalyn Pharma AVLN | $1.29B | +7% | n/a | n/a | n/a | n/a |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
| United Therapeutics UTHR | $24.1B | -1% | +2% | 44% | 6.9× | -0.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVLN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.3% | -7.6% | 3rd highest of 21 |
| 6-month return | +6.7% | -10.9% | 6th highest of 21 |
| Distance from 52-week high | -27.4% | -40.5% | 6th highest of 21 |
| ROIC minus cost of capital | -127.6 pp | -5.0 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |